146 related articles for article (PubMed ID: 20406667)
1. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review.
Szenajch J; Wcislo G; Jeong JY; Szczylik C; Feldman L
Biochim Biophys Acta; 2010 Aug; 1806(1):82-95. PubMed ID: 20406667
[TBL] [Abstract][Full Text] [Related]
2. The distinct erythropoietin functions that promote cell survival and proliferation are affected by aluminum exposure through mechanisms involving erythropoietin receptor.
Vittori D; Pregi N; Pérez G; Garbossa G; Nesse A
Biochim Biophys Acta; 2005 Mar; 1743(1-2):29-36. PubMed ID: 15777837
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin biology in cancer.
Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
[TBL] [Abstract][Full Text] [Related]
5. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
Chen J; Jacobs-Helber SM; Barber DL; Sawyer ST
Exp Cell Res; 2004 Aug; 298(1):155-66. PubMed ID: 15242770
[TBL] [Abstract][Full Text] [Related]
7. The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.
Hu W; Zhang Y; Jiang Z; Wang L; Li J; Chen S; Dai N; Si J
Tumour Biol; 2016 Aug; 37(8):11523-33. PubMed ID: 27086036
[TBL] [Abstract][Full Text] [Related]
8. Functional significance of erythropoietin receptor on tumor cells.
Udupa KB
World J Gastroenterol; 2006 Dec; 12(46):7460-2. PubMed ID: 17167833
[TBL] [Abstract][Full Text] [Related]
9. Functional erythropoietin autocrine loop in melanoma.
Kumar SM; Acs G; Fang D; Herlyn M; Elder DE; Xu X
Am J Pathol; 2005 Mar; 166(3):823-30. PubMed ID: 15743794
[TBL] [Abstract][Full Text] [Related]
10. [Erythropoietin and drug resistance in breast and ovarian cancers].
Szenajch JM; Synowiec AE
Ginekol Pol; 2016; 87(4):300-4. PubMed ID: 27321103
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
12. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis.
Leo C; Horn LC; Rauscher C; Hentschel B; Liebmann A; Hildebrandt G; Höckel M
Clin Cancer Res; 2006 Dec; 12(23):6894-900. PubMed ID: 17145806
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Asymmetry of Activated EPO Receptor Enables Designing Small Molecule Agonists.
Guarnieri F
Vitam Horm; 2017; 105():19-37. PubMed ID: 28629518
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.
Diensthuber M; Ilner T; Rodt T; Samii M; Brandis A; Lenarz T; Stöver T
Otol Neurotol; 2007 Jun; 28(4):559-65. PubMed ID: 17429338
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin and the heart: physiological effects and the therapeutic perspective.
Sanchis-Gomar F; Garcia-Gimenez JL; Pareja-Galeano H; Romagnoli M; Perez-Quilis C; Lippi G
Int J Cardiol; 2014 Feb; 171(2):116-25. PubMed ID: 24377712
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.
Arcasoy MO; Karayal AF
Biochim Biophys Acta; 2005 Apr; 1740(1):17-28. PubMed ID: 15878737
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.
Larsson AM; Jirström K; Fredlund E; Nilsson S; Rydén L; Landberg G; Påhlman S
Clin Cancer Res; 2009 Sep; 15(17):5552-9. PubMed ID: 19706814
[TBL] [Abstract][Full Text] [Related]
19. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis.
Menon MP; Karur V; Bogacheva O; Bogachev O; Cuetara B; Wojchowski DM
J Clin Invest; 2006 Mar; 116(3):683-94. PubMed ID: 16511603
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma.
Acs G; Zhang PJ; Rebbeck TR; Acs P; Verma A
Cancer; 2002 Sep; 95(5):969-81. PubMed ID: 12209679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
